Rockwell sells Indian rights to anemia product Triferic

15 January 2020

American anemia specialist Rockwell Medical (Nasdaq: RMTI) has entered into a license and supply agreement with Sun Pharmaceutical (BSE: 524715), providing rights to commercialize Triferic (ferric pyrophosphate citrate) in India.

Sun Pharma will be the exclusive development and commercialization partner for Triferic in India. Rockwell Medical will supply the product, in return for an upfront fee, milestone payments and royalties on net sales.

Triferic is the only US Food and Drug Administration-approved therapy to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment. The US regulator approved the therapy in 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK